Last Updated: October 3, 2025
Analyzing Management
Leadership at public companies serves as a crucial variable for hedge funds and asset managers during both initial due diligence and continuous risk assessment. ManagementTrack offers a consistent methodology that filters out distractions—highlighting specific strengths and weaknesses, identifying red and green flags, and drawing a straightforward connection between CEO actions and investment outcomes.
CEO Pfeil’s past struggles threaten NuVasive integration and core market share
Analysis of Globus Medical CEO Keith Pfeil
Given a history of M&A challenges and organic sales declines, Keith Pfeil appears poorly aligned with the company’s critical need to execute the NuVasive integration and drive core market share gains.
Management evaluated Keith Pfeil’s track record and skillset against the following key factors for GMED:
- Integrating NuVasive manufacturing to achieve margin targets.
- Sustaining US Spine momentum to validate the NuVasive merger.
- Realizing NuVasive merger synergies to hit financial targets.
- Executing the turnaround of the struggling Nevro acquisition.
Keith Pfeil’s Track Record & Key Open Questions to Research
ManagementTrack provides track record analysis, career playbooks, strengths, and weaknesses for every CEO. It allows investors to dig deeper to uncover hard to find data to answer the most pressing questions.
Reach out to sales@paragonintel.com or visit https://paragonintel.com/access-now/ for more information.
Question #1
When forced to choose between hitting near-term synergy targets and investing to fix the underlying operational issues that caused the initial integration failure, which path will Pfeil prioritize?
Question #2
Given the massive credibility gap that emerged after the Q1 2025 earnings miss, will Pfeil prioritize transparent communication about integration challenges to rebuild investor trust, or will he maintain a controlled narrative that risks further surprising the market?
Question #3
With his background rooted in finance and a track record at CSS Industries of failed M&A-led growth, does Pfeil possess the commercial instincts to drive sustained top-line momentum in the core U.S. Spine business, or will his focus remain primarily on financial engineering and cost management?
Why Do Investors Use ManagementTrack?
Q: How does ManagementTrack evaluate Keith Pfeil’s leadership at GMED?
A: ManagementTrack assesses Keith Pfeil through its proprietary career analysis and interviews with former colleagues. This process builds a detailed profile of his track record, core competencies, and potential weaknesses. His abilities are then mapped against GMED’s most critical challenges: integrating NuVasive manufacturing to achieve margin targets, sustaining momentum in the US Spine market, realizing the full financial synergies of the merger, and executing the turnaround of the Nevro acquisition.
Q: What additional proprietary signals does ManagementTrack analyze to connect executive actions to future performance?
A: ManagementTrack employs proprietary models to identify abnormal instances of executive evasion during earnings call Q&A. Its platform also analyzes the full universe of insider transactions to isolate outlier trades that are predictive of future stock performance. When synthesized with the ManagementTrack Rating, a predictive 1-10 score assigned to each executive, these signals give investors a clear, forward-looking view on management’s potential impact on shareholder value.
Q: What is the scope of ManagementTrack’s coverage?
A: ManagementTrack maintains real-time coverage on the C-suite of every publicly listed company.
How to Learn More
Reach out to sales@paragonintel.com or visit https://paragonintel.com/access-now/ to see our deep dive analysis on any executive.
Author
Author: Colby Howard is the co-founder and President of Paragon Intel. Paragon Intel’s ManagementTrack is the premier executive analysis platform for hedge funds, asset managers, corporations, boards, and recruiters. Our proprietary data, built over a decade of analysis, allows us to analyze each public company executive to understand their fit and ability to execute at their company. We leverage our proprietary data – key quantitative research on an executive’s career plus interviews with their former colleagues – with public documents, including SEC filings (10-K, 10-Q), investor presentations, press releases, and earnings call transcripts. to build a holistic, evidence-based view of an executive’s capabilities and playbook.
Sources
- Verified Career History by ManagementTrack for Keith Pfeil
- Analysis of Capital Allocation, Performance, and Fundamentals across career by ManagementTrack
- Globus Medical, Inc. 10Q
- Globus Medical, Inc. 10K
- Globus Medical, Inc. Earnings Calls
- Globus Medical, Inc. Press Releases
Relevant Links
- For more information on ManagementTrack’s Data visit: https://paragonintel.com/management-track-data/
- For more information on ManagementTrack’s Interview & Analysis visit: https://paragonintel.com/management-track-reports/
- For more information on ManagementTrack’s Interview library visit: https://paragonintel.com/management-track-report-library/
- For more information on ManagementTrack’s Evasion Analysis visit: https://paragonintel.com/earnings-call-evasion/
- For more information on how ManagementTrack helps hedge funds and asset managers visit: https://paragonintel.com/
